American Journal of Kidney Diseases
Volume 55, Issue 1 , Pages 168-180 , January 2010

Posttransplant Lymphoproliferative Disorder Following Kidney Transplant

  • Alicia K. Morgans, MD

      Affiliations

    • Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
    • ,
  • Ran Reshef, MD

      Affiliations

    • Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
    • Institute of Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA
    • ,
  • Donald E. Tsai, MD, PhD

      Affiliations

    • Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
    • Corresponding Author InformationAddress correspondence to Donald E. Tsai, MD, PhD, 2 PCAM, Abramson Cancer Center, 3400 Civic Center Blvd, Philadelphia, PA 19104

Received 8 July 2009 ,Accepted 30 September 2009.

References 

  1. National Data for Kidney and Kidney/Pancreas Transplants (Organ Procurement and Transplantation Network). 2009;http://optn.transplant.hrsa.gov/data/Accessed July 12, 2009
  2. Frey NV, Tsai DE. The management of posttransplant lymphoproliferative disorder. Med Oncol. 2007;24(2):125–136
  3. Yang J, Tao Q, Flinn IW, et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood. 2000;96(13):4055–4063
  4. Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000;343(7):481–492
  5. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. [see comment] N Engl J Med. 2004;350(13):1328–1337
  6. Reshef R, Luskin M, Morgans A, et al. EBV-negative PTLD: 20 year experience in a large transplant center. In: Paper presented at: American Transplant Congress. Boston, MA. May 30-June 3, 2009;
  7. Fields BN, Knipe DM, Howley PM. Fields' Virology. 5th ed.. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007;
  8. Gulley ML, Swinnen LJ, Plaisance KT, et al. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy. Transplantation. 2003;76(6):959–964
  9. Epstein MA, Achong BG, Pope JH. Virus in cultured lymphoblasts from a New Guinea Burkitt lymphoma. Br Med J. 1967;2(5547):290–291
  10. Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med. 1989;320(8):502–506
  11. Swerdlow SH International Agency for Research on Cancer, World Health Organization. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed.. Lyon, France: International Agency for Research on Cancer; 2008;
  12. Ghobrial IM, Habermann TM, Maurer MJ, et al. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol. 2005;23(30):7574–7582
  13. Trofe J, Buell JF, Beebe TM, et al. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience. Am J Transplant. 2005;5(4 pt 1):775–780
  14. Shroff R, Rees L. The post-transplant lymphoproliferative disorder—a literature review. [see comment] Pediatr Nephrol. 2004;19(4):369–377
  15. Dharnidharka VR, Tejani AH, Ho PL, Harmon WE. Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk. Am J Transplant. 2002;2(10):993–998
  16. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4(2):222–230
  17. Ghobrial IM, Habermann TM, Ristow KM, et al. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma. 2005;46(2):191–196
  18. Nalesnik MA. Clinicopathologic characteristics of post-transplant lymphoproliferative disorders. Recent Results Cancer Res. 2002;159:9–18
  19. Leblond V, Dhedin N, Mamzer Bruneel MF, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol. 2001;19(3):772–778
  20. Boubenider S, Hiesse C, Goupy C, Kriaa F, Marchand S, Charpentier B. Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol. 1997;10(3):136–145
  21. Sokal EM, Antunes H, Beguin C, et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation. 1997;64(10):1438–1442
  22. Shroff R, Trompeter R, Cubitt D, Thaker U, Rees L. Epstein-Barr virus monitoring in paediatric renal transplant recipients. Pediatr Nephrol. 2002;17(9):770–775
  23. Shahinian VB, Muirhead N, Jevnikar AM, et al. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoproliferative disorder in adult renal allograft recipients. Transplantation. 2003;75(6):851–856
  24. Finn L, Reyes J, Bueno J, Yunis E. Epstein-Barr virus infections in children after transplantation of the small intestine. Am J Surg Pathol. 1998;22(3):299–309
  25. Cohen JI. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine (Baltimore). 1991;70(2):137–160
  26. Nalesnik MA, Rao AS, Furukawa H, et al. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation. 1997;63(9):1200–1205
  27. Harwood JS, Gould FK, McMaster A, et al. Significance of Epstein-Barr virus status and post-transplant lymphoproliferative disease in pediatric thoracic transplantation. Pediatr Transplant. 1999;3(2):100–103
  28. Newell KA, Alonso EM, Kelly SM, Rubin CM, Thistlethwaite JR, Whitington PF. Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children. J Pediatr. 1997;131(1 pt 1):98–104
  29. Ho M, Jaffe R, Miller G, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation. 1988;45(4):719–727
  30. Herzig KA, Juffs HG, Norris D, et al. A single-centre experience of post-renal transplant lymphoproliferative disorder. Transpl Int. 2003;16(7):529–536
  31. Luskin M, Reshef R, Vardhanabhuti S, et al. Association of HLA polymorphisms with PTLD in organ transplant recipients. In: Paper presented at: American Transplant Congress. Boston, MA. May 30-June 3, 2009;
  32. Bakker NA, van Imhoff GW, Verschuuren EA, et al. HLA antigens and post renal transplant lymphoproliferative disease: HLA-B matching is critical. Transplantation. 2005;80(5):595–599
  33. Subklewe M, Marquis R, Choquet S, et al. Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation. Transplantation. 2006;82(8):1093–1100
  34. Pourfarziani V, Einollahi B, Taheri S, Nemati E, Nafar M, Kalantar E. Associations of human leukocyte antigen (HLA) haplotypes with risk of developing lymphoproliferative disorders after renal transplantation. Ann Transplant. 2007;12(4):16–22
  35. Tsai DE, Nearey M, Hardy CL, et al. Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients. Am J Transplant. 2002;2(10):946–954
  36. Riddler SA, Breinig MC, McKnight JL. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood. 1994;84(3):972–984
  37. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol. 1995;89(1):98–103
  38. Savoie A, Perpete C, Carpentier L, Joncas J, Alfieri C. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood. 1994;83(9):2715–2722
  39. Kenagy DN, Schlesinger Y, Weck K, Ritter JH, Gaudreault-Keener MM, Storch GA. Epstein-Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease. Transplantation. 1995;60(6):547–554
  40. Lucas KG, Burton RL, Zimmerman SE, et al. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood. 1998;91(10):3654–3661
  41. McDiarmid SV, Jordan S, Kim GS, et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation. 1998;66(12):1604–1611
  42. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006;6(2):262–274
  43. Tsai DE, Douglas L, Andreadis C, et al. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am J Transplant. 2008;8(5):1016–1024
  44. Nalesnik MA. Posttransplantation lymphoproliferative disorders (PTLD): current perspectives. Semin Thorac Cardiovasc Surg. 1996;8(2):139–148
  45. Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation. 2001;71(8):1076–1088
  46. Penn I. Primary kidney tumors before and after renal transplantation. Transplantation. 1995;59(4):480–485
  47. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol. 2005;56(1):155–167
  48. Martinez AJ, Ahdab-Barmada M. The neuropathology of liver transplantation: comparison of main complications in children and adults. Mod Pathol. 1993;6(1):25–32
  49. Kew CE, Lopez-Ben R, Smith JK, et al. Postransplant lymphoproliferative disorder localized near the allograft in renal transplantation. Transplantation. 2000;69(5):809–814
  50. Epstein-Barr virus and lymphoproliferative disorders after transplantation. Am J Transplant. 2004;4(suppl 10):S59–S65
  51. Foon KA, Ghobrial I, Geskin L, Jacobs SA. The Non-Hodgkin lymphomas. In:  Lichtman MA,  Kipps TJ,  Kaushansky K,  Beutler E,  Seligsohn U,  Prchal JT editor. Williams Hematology. 7th ed.. New York, NY: McGraw-Hill Medical Pub Division; 2006;
  52. Reshef R, Morgans AK, Tsai DE. Post-transplant lymphoproliferative disorder. In:  Lazarus HM,  Laughlin MJ editor. Allogeneic Stem-Cell Transplantation. 2nd ed.. New York, NY: Humana Press; 2010;
  53. Colby BM, Shaw JE, Elion GB, Pagano JS. Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication. J Virol. 1980;34(2):560–568
  54. Crumpacker CS. Ganciclovir. N Engl J Med. 1996;335(10):721–729
  55. Faller DV, Mentzer SJ, Perrine SP. Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol. 2001;13(5):360–367
  56. Perrine SP, Hermine O, Small T, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood. 2007;109(6):2571–2578
  57. Davis CL, Wood BL, Sabath DE, Joseph JS, Stehman-Breen C, Broudy VC. Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation. 1998;66(12):1770–1779
  58. Hauke R, Smir B, Greiner T, et al. Clinical and pathological features of posttransplant lymphoproliferative disorders: influence on survival and response to treatment. Ann Oncol. 2001;12(6):831–834
  59. Benkerrou M, Durandy A, Fischer A. Therapy for transplant-related lymphoproliferative diseases. Hematol Oncol Clin North Am. 1993;7(2):467–475
  60. Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant. 2006;6(3):569–576
  61. Kang SK, Kirkpatrick JP, Halperin EC. Low-dose radiation for posttransplant lymphoproliferative disorder. Am J Clin Oncol. 2003;26(2):210–214
  62. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. 1984;1(8377):583–587
  63. Loren AW, Tsai DE. Post-transplant lymphoproliferative disorder. Clin Chest Med. 2005;26(4):631–645
  64. Leblond V, Davi F, Charlotte F, et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?. J Clin Oncol. 1998;16(6):2052–2059
  65. Nelson BP, Nalesnik MA, Bahler DW, Locker J, Fung JJ, Swerdlow SH. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?. Am J Surg Pathol. 2000;24(3):375–385
  66. Faye A, Van Den Abeele T, Peuchmaur M, Mathieu-Boue A, Vilmer E. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders [letter]. Lancet. 1998;352(9136):1285
  67. Fischer A, Blanche S, Le Bidois J, et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med. 1991;324(21):1451–1456
  68. Kuehnle I, Huls MH, Liu Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000;95(4):1502–1505
  69. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol. 2000;11(suppl 1):S113–S116
  70. Benkerrou M, Jais JP, Leblond V, et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood. 1998;92(9):3137–3147
  71. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med. 2008;359(6):613–626
  72. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113(20):4834–4840
  73. Dotti G, Fiocchi R, Motta T, et al. Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation. 2002;74(8):1095–1102
  74. Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood. 1995;86(9):3333–3340
  75. Mamzer-Bruneel MF, Lome C, Morelon E, et al. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: a report of 16 cases observed in a single center. J Clin Oncol. 2000;18(21):3622–3632
  76. Gill D, Juffs HG, Herzig KA, et al. Durable and high rates of remission following chemotherapy in posttransplantation lymphoproliferative disorders after renal transplantation. Transplant Proc. 2003;35(1):256–257
  77. Heslop HE, Savoldo B, Rooney CM. Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease. Best Pract Res Clin Haematol. 2004;17(3):401–413
  78. Porter DL, Orloff GJ, Antin JH. Donor mononuclear cell infusions as therapy for B-cell lymphoproliferative disorder following allogeneic bone marrow transplant. Transplant Sci. 1994;4(1):12–14
  79. Bollard CM, Savoldo B, Rooney CM, Heslop HE. Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. Acta Haematol. 2003;110(2-3):139–148
  80. Haque T, Taylor C, Wilkie GM, et al. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation. 2001;72(8):1399–1402
  81. Khanna R, Bell S, Sherritt M, et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci U S A. 1999;96(18):10391–10396
  82. Savoldo B, Goss J, Liu Z, et al. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation. 2001;72(6):1078–1086
  83. Savoldo B, Goss JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006;108(9):2942–2949
  84. Comoli P, Labirio M, Basso S, et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood. 2002;99(7):2592–2598
  85. Haque T, Wilkie GM, Taylor C, et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet. 2002;360(9331):436–442
  86. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110(4):1123–1131
  87. Birkeland SA, Hamilton-Dutoit S, Bendtzen K. Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation. Transplantation. 2003;76(1):153–158
  88. Hanto DW. Retransplantation after post-transplant lymphoproliferative diseases (PTLD): when is it safe?. Am J Transplant. 2004;4(11):1733–1734
  89. Karras A, Thervet E, Le Meur Y, Baudet-Bonneville V, Kessler M, Legendre C. Successful renal retransplantation after post-transplant lymphoproliferative disease. Am J Transplant. 2004;4(11):1904–1909
  90. Johnson SR, Cherikh WS, Kauffman HM, Pavlakis M, Hanto DW. Retransplantation after post-transplant lymphoproliferative disorders: an OPTN/UNOS database analysis. Am J Transplant. 2006;6(11):2743–2749

 Originally published online as doi:10.1053/j.ajkd.2009.09.026 on December 7, 2009.

 A.K. Morgans and R. Reshef contributed equally to this manuscript.

PII: S0272-6386(09)01312-2

doi: 10.1053/j.ajkd.2009.09.026

American Journal of Kidney Diseases
Volume 55, Issue 1 , Pages 168-180 , January 2010

Article Tools

* Image Usage & Resolution